Selected research
Industry Research
Cell-Free Circulating Tumor DNA (ctDNA) Industry Research Report 2026
Market perspective
The global Cell-Free Circulating Tumor DNA (ctDNA) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Cell-Free Circulating Tumor DNA (ctDNA) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Cell-Free Circulating Tumor DNA (ctDNA) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Cell-Free Circulating Tumor DNA (ctDNA) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Cell-Free Circulating Tumor DNA (ctDNA) include Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis and QIAGEN, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Cell-Free Circulating Tumor DNA (ctDNA) market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Cell-Free Circulating Tumor DNA (ctDNA).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cell-Free Circulating Tumor DNA (ctDNA) Market by Company
Nexomics
Roche
ORIOMICS
Signatera
Illumina
Sysmex Corporation
Bio-Rad
Biocartis
QIAGEN
GuardantHealth
GSK plc
AstraZeneca
NeoGenomics Laboratories
AmoyDx
Annoroad
Burning Rock Biotech
Cell-Free Circulating Tumor DNA (ctDNA) Segment by Type
Gastric Cancer Methylation Screening
Esophageal Cancer Methylation Screening
Colorectal Cancer Methylation Screening
Lung Cancer Methylation Screening
Liver Cancer Methylation Screening
Other Cancer Screening
Cell-Free Circulating Tumor DNA (ctDNA) Segment by Application
Hospital
Medical Center
Laboratory
Cell-Free Circulating Tumor DNA (ctDNA) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell-Free Circulating Tumor DNA (ctDNA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cell-Free Circulating Tumor DNA (ctDNA) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell-Free Circulating Tumor DNA (ctDNA).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Cell-Free Circulating Tumor DNA (ctDNA) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Gastric Cancer Methylation Screening
- Esophageal Cancer Methylation Screening
- Colorectal Cancer Methylation Screening
- Lung Cancer Methylation Screening
- Liver Cancer Methylation Screening
- Other Cancer Screening
Applications
- Hospital
- Medical Center
- Laboratory
Companies covered
- Nexomics
- Roche
- ORIOMICS
- Signatera
- Illumina
- Sysmex Corporation
- Bio-Rad
- Biocartis
- QIAGEN
- GuardantHealth
- GSK plc
- AstraZeneca
- NeoGenomics Laboratories
- AmoyDx
- Annoroad
- Burning Rock Biotech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cell-Free Circulating Tumor DNA (ctDNA) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Gastric Cancer Methylation Screening
- 2.2.3 Esophageal Cancer Methylation Screening
- 2.2.4 Colorectal Cancer Methylation Screening
- 2.2.5 Lung Cancer Methylation Screening
- 2.2.6 Liver Cancer Methylation Screening
- 2.2.7 Other Cancer Screening
- 2.3 Cell-Free Circulating Tumor DNA (ctDNA) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Medical Center
- 2.3.4 Laboratory
- 2.4 Assumptions and Limitations
3 Cell-Free Circulating Tumor DNA (ctDNA) Breakdown Data by Type
- 3.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size by Type (2021-2026)
- 3.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Type (2027-2032)
4 Cell-Free Circulating Tumor DNA (ctDNA) Breakdown Data by Application
- 4.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size by Application (2021-2026)
- 4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Perspective (2021-2032)
- 5.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Growth Trends by Region
- 5.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size by Region (2021-2026)
- 5.2.3 Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Region (2027-2032)
- 5.3 Cell-Free Circulating Tumor DNA (ctDNA) Market Dynamics
- 5.3.1 Cell-Free Circulating Tumor DNA (ctDNA) Industry Trends
- 5.3.2 Cell-Free Circulating Tumor DNA (ctDNA) Market Drivers
- 5.3.3 Cell-Free Circulating Tumor DNA (ctDNA) Market Challenges
- 5.3.4 Cell-Free Circulating Tumor DNA (ctDNA) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Revenue
- 6.1.1 Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Revenue (2021-2026)
- 6.1.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Players (2021-2026)
- 6.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Cell-Free Circulating Tumor DNA (ctDNA) Head Office and Area Served
- 6.4 Global Cell-Free Circulating Tumor DNA (ctDNA) Players, Product Type & Application
- 6.5 Global Cell-Free Circulating Tumor DNA (ctDNA) Manufacturers Established Date
- 6.6 Global Cell-Free Circulating Tumor DNA (ctDNA) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
- 7.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
- 7.4 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
- 8.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
- 8.4 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
- 9.2 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
- 10.2 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
- 10.4 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
- 11.2 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Nexomics
- 12.1.1 Nexomics Company Information
- 12.1.2 Nexomics Business Overview
- 12.1.3 Nexomics Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.1.4 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.1.5 Nexomics Recent Developments
- 12.2 Roche
- 12.2.1 Roche Company Information
- 12.2.2 Roche Business Overview
- 12.2.3 Roche Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.2.4 Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.2.5 Roche Recent Developments
- 12.3 ORIOMICS
- 12.3.1 ORIOMICS Company Information
- 12.3.2 ORIOMICS Business Overview
- 12.3.3 ORIOMICS Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.3.4 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.3.5 ORIOMICS Recent Developments
- 12.4 Signatera
- 12.4.1 Signatera Company Information
- 12.4.2 Signatera Business Overview
- 12.4.3 Signatera Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.4.4 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.4.5 Signatera Recent Developments
- 12.5 Illumina
- 12.5.1 Illumina Company Information
- 12.5.2 Illumina Business Overview
- 12.5.3 Illumina Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.5.4 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.5.5 Illumina Recent Developments
- 12.6 Sysmex Corporation
- 12.6.1 Sysmex Corporation Company Information
- 12.6.2 Sysmex Corporation Business Overview
- 12.6.3 Sysmex Corporation Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.6.4 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.6.5 Sysmex Corporation Recent Developments
- 12.7 Bio-Rad
- 12.7.1 Bio-Rad Company Information
- 12.7.2 Bio-Rad Business Overview
- 12.7.3 Bio-Rad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.7.4 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.7.5 Bio-Rad Recent Developments
- 12.8 Biocartis
- 12.8.1 Biocartis Company Information
- 12.8.2 Biocartis Business Overview
- 12.8.3 Biocartis Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.8.4 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.8.5 Biocartis Recent Developments
- 12.9 QIAGEN
- 12.9.1 QIAGEN Company Information
- 12.9.2 QIAGEN Business Overview
- 12.9.3 QIAGEN Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.9.4 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.9.5 QIAGEN Recent Developments
- 12.10 GuardantHealth
- 12.10.1 GuardantHealth Company Information
- 12.10.2 GuardantHealth Business Overview
- 12.10.3 GuardantHealth Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.10.4 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.10.5 GuardantHealth Recent Developments
- 12.11 GSK plc
- 12.11.1 GSK plc Company Information
- 12.11.2 GSK plc Business Overview
- 12.11.3 GSK plc Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.11.4 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.11.5 GSK plc Recent Developments
- 12.12 AstraZeneca
- 12.12.1 AstraZeneca Company Information
- 12.12.2 AstraZeneca Business Overview
- 12.12.3 AstraZeneca Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.12.4 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.12.5 AstraZeneca Recent Developments
- 12.13 NeoGenomics Laboratories
- 12.13.1 NeoGenomics Laboratories Company Information
- 12.13.2 NeoGenomics Laboratories Business Overview
- 12.13.3 NeoGenomics Laboratories Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.13.4 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.13.5 NeoGenomics Laboratories Recent Developments
- 12.14 AmoyDx
- 12.14.1 AmoyDx Company Information
- 12.14.2 AmoyDx Business Overview
- 12.14.3 AmoyDx Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.14.4 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.14.5 AmoyDx Recent Developments
- 12.15 Annoroad
- 12.15.1 Annoroad Company Information
- 12.15.2 Annoroad Business Overview
- 12.15.3 Annoroad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.15.4 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.15.5 Annoroad Recent Developments
- 12.16 Burning Rock Biotech
- 12.16.1 Burning Rock Biotech Company Information
- 12.16.2 Burning Rock Biotech Business Overview
- 12.16.3 Burning Rock Biotech Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2021-2026)
- 12.16.4 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Portfolio
- 12.16.5 Burning Rock Biotech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst